Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07213674 · ClinicalTrials.gov registry record · Phase 3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Amgen.

Recruiting
Registry status
Phase 3
Development phase
750
Enrollment target
20
Study locations

NCT07213674: Recruiting Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Amgen.

NCT07213674 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 750 participants, above the 187-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (301% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07213674, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 3
Development phase
750 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Xaluritamig
  • DRUG Cabazitaxel
  • DRUG Abiraterone acetate

Study Locations (20)

Other

  • Ordensklinikum Linz Elisabethinen - Linz
  • Universitaetsklinikum Sankt Poelten - Sankt Pölten
  • Krankenhaus der Barmherzigen Brueder Wien - Vienna
  • Universitaetsklinikum Allgemeines Krankenhaus Wien - Vienna

California

  • City of Hope National Medical Center - Duarte
  • City of Hope Orange County Lennar Foundation Cancer Center - Duarte
  • Providence Saint Jude Medical Center - Fullerton

Queensland

  • Icon Cancer Care Wesley - Herston
  • Tasman Oncology Research - Southport

Victoria

  • Monash Medical Centre - Clayton
  • Austin Health, Austin Hospital - East Melbourne

Colorado

  • Rocky Mountain Cancer Centers - Denver

Illinois

  • University of Illinois Chicago - Chicago

Kentucky

  • Norton Cancer Institute - Louisville

Ohio

  • Oncology Hematology Care Incorporated - Cincinnati

Trial Details

FieldValue
Enrollment Target 750 participants
Start Date 2025-11-28
Est. Completion 2032-08-30
Phase Phase 3
Amgen

558 total trials

What NCT07213674 shows while recruiting

NCT07213674 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 187-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (301% higher).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.

NCT07213674 names 20 study sites across 13 states, led by Other, California, Queensland.

Frequently Asked Questions

What is clinical trial NCT07213674 about?

NCT07213674 is a clinical study titled "A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer". The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

What is the current status of trial NCT07213674?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2025-11-28. Estimated completion is 2032-08-30.

What conditions does trial NCT07213674 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT07213674?

The interventions under investigation include: Docetaxel (DRUG), Xaluritamig (DRUG), Cabazitaxel (DRUG), Abiraterone acetate (DRUG).

Who is sponsoring clinical trial NCT07213674?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07213674 being conducted?

This trial has 20 study locations across California, Colorado, Illinois, Kentucky, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07213674's enrollment target sits among peer trials

750 6th of 69 higher than 64 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02048332 · 750 participants · Phase 1

    Donor-Derived Viral Specific T-cells (VSTs)

  • NCT02087852 · 750 participants

    Kidney Cancer DNA Registry

  • NCT02532452 · 750 participants · Phase 2

    Third Party Viral Specific T-cells (VSTs)

  • NCT03126916 · 750 participants · Phase 3

    Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07213674

Source: ClinicalTrials.gov NCT07213674, the US trial registry maintained by the National Library of Medicine. NCT07213674 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.